Physician profile
Emma Ruinsky
NPI 1588990956
$6,601.44
in general payments reported to CMS, 2019-2025
20 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $1,245 · 2023: $2,002 · 2024: $1,441 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,995 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.01 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,618.63 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,107.22 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $744.03 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $526.99 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $453.73 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $437.87 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $407.79 | 2021-2024 | Spravato |
| Lundbeck LLC | $398.37 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.09 | 2022-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $165.56 | 2023-2025 | |
| Corium, LLC | $147.09 | 2022 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Almatica Pharma LLC | $104.40 | 2024 | Loreev Xr, Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $74.19 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $30.71 | 2025 | Nuplazid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.68 | 2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $21.67 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $18.87 | 2023 | Adzenys Xr-Odt |
| Urovant Sciences INC | $18.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Ruinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.